Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
13.84
-0.43 (-3.01%)
At close: Apr 28, 2026, 4:00 PM EDT
13.37
-0.47 (-3.43%)
After-hours: Apr 28, 2026, 7:01 PM EDT
Trevi Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 15.85 | 12.15 | 10.24 | 10.07 | 9.49 | |
| Research & Development | 33.48 | 39.38 | 23.68 | 19.83 | 22.98 | |
| Operating Expenses | 49.33 | 51.52 | 33.92 | 29.91 | 32.48 | |
| Operating Income | -49.33 | -51.52 | -33.92 | -29.91 | -32.48 | |
| Interest Expense | - | -0 | -0.39 | -1.16 | -1.2 | |
| Interest & Investment Income | 6.54 | 3.6 | 4.75 | 1.74 | 0.01 | |
| Other Non Operating Income (Expenses) | -0.03 | -0.02 | 0.47 | 0.14 | -0.29 | |
| EBT Excluding Unusual Items | -42.82 | -47.94 | -29.1 | -29.19 | -33.96 | |
| Pretax Income | -42.82 | -47.94 | -29.1 | -29.19 | -33.96 | |
| Income Tax Expense | -0.06 | -0.03 | -0.03 | -0.04 | -0.02 | |
| Net Income | -42.76 | -47.91 | -29.07 | -29.15 | -33.94 | |
| Net Income to Common | -42.76 | -47.91 | -29.07 | -29.15 | -33.94 | |
| Shares Outstanding (Basic) | 135 | 102 | 99 | 65 | 23 | |
| Shares Outstanding (Diluted) | 135 | 102 | 99 | 65 | 23 | |
| Shares Change (YoY) | 32.14% | 2.97% | 53.44% | 182.56% | 26.48% | |
| EPS (Basic) | -0.32 | -0.47 | -0.29 | -0.45 | -1.49 | |
| EPS (Diluted) | -0.32 | -0.47 | -0.29 | -0.45 | -1.49 | |
| Free Cash Flow | -42.1 | -38.29 | -31.85 | -28.33 | -28.95 | |
| Free Cash Flow Per Share | -0.31 | -0.38 | -0.32 | -0.44 | -1.27 | |
| EBITDA | -49.18 | -51.38 | -33.8 | -29.86 | -32.43 | |
| D&A For EBITDA | 0.14 | 0.15 | 0.12 | 0.04 | 0.05 | |
| EBIT | -49.33 | -51.52 | -33.92 | -29.91 | -32.48 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.